The San Francisco Business Times highlights new Series B funding for Nura Bio Inc., founded eight years ago based off research by OHSU researcher Marc Freeman, Ph.D., taking the company’s total funding to more than $217 million.

NBC News reports on new research that found that severe muscular problems when taking statins is an exceedingly rare side effect, and patients should weigh the risks and benefits with their clinician. Bart Duell, M.D., says, “Even if you increase that tenfold, that is still a very tiny risk. … The risk of muscular side effects really isn’t a reason to not use statins.”

OPB-Radio reports on the possibility of the FDA easing restrictions on some peptides and off-label prescriptions. Daniel Hartung, Pharm.D., says, “Allowing compounders to access products through more regulated sources does potentially improve the safety of it. … Frankly, a lot of these things we still don’t what know their efficacy is, or the short term or long-term safety. This could continue to accelerate their use in the population when we really don’t have good information or evidence for what these things are actually doing for some of these agents.”

STAT News publishes an opinion piece evaluating the ethical questions of human embryo gene editing, citing research by Shoukhrat Mitalipov, Ph.D.

Medpage Today reports on new research that urges the FDA to require negative studies of a new drug to be included in the product’s labeling, not just those studies with a beneficial finding, to prevent physicians and consumers from being misled about the drug’s safety and efficacy. Erick Turner, M.D., says, “The gepirone labeling represents a cherry-picked subset of studies, and for those, [the FDA] relied on statistical significance as opposed to clinical significance ... with a very tiny margin of advantage over placebo for all the studies combined: less than a half a point difference on the Hamilton Depression Rating Scale.”

Lisa Coussens, Ph.D., is among the recipients of a Leadership Grant from the Susan G. Komen Foundation.

Healio Cardiology reports on the Care of the Athletic Heart preconference, including Bradley Petek, M.D., providing an overview of original research in sports cardiology published since January 2025.

Biospace reports that Nura Bio has raised $73.8 million in financing to carry two neuroprotective drug candidates through early to mid-stage clinical studies, including one to target ALS. Marc Freeman, Ph.D., is the company’s academic co-founder who conducted preclinical research that found the SARM1 protein played a role in axon degeneration in fly and mammalian models.

Oregon Institute of Technology presents its first honorary doctorate to Shereef Elnahal, M.D., M.B.A., during its 2026 commencement ceremony, where Elnahal was the keynote speaker.

Psychedelic Alpha interviews Chris Stauffer, M.D., about his work in MDMA-assisted group therapy for military veterans.